Ronald Harris, MD
Dermatopathology · Austin, TXNPI 1215033501
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Genentech USA, Inc. at 44.7% of the total. Reporting peaked in 2019 at $6,709 and has fallen 57.2% since, to $2,871 in 2025.
Across 334 payments — averaging $41.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$6K
- AbbVie$1K
- Sanofi$774
- Johnson & Johnson$729
- Regeneron Healthcare Solutions, Inc.$720
- Amgen$502
- plus $4K from 26 others
Across 4 payments — averaging $3082.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$10K
- Eli Lilly$2K
What the payments were for
- Speaking & faculty fees$5,24038%
- Travel & lodging$6565%
- Food & beverage$7,97457%
- Education$931%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 7 | $6,242 |
| AbbVie | 48 | $1,009 |
| Sanofi | 21 | $774 |
| Johnson & Johnson | 43 | $729 |
| Regeneron Healthcare Solutions, Inc. | 32 | $720 |
| Amgen | 22 | $502 |
| Novartis | 24 | $499 |
| Sun Pharmaceutical Industries Inc. | 14 | $391 |
| Arcutis Biotherapeutics, Inc. | 15 | $359 |
| Janssen Scientific Affairs, LLC | 2 | $299 |
| E.r. Squibb & Sons, L.L.C. | 7 | $298 |
| UCB, Inc. | 11 | $298 |
| Merz North America, Inc. | 1 | $241 |
| Lilly USA, LLC | 10 | $215 |
| LEO Pharma Inc. | 10 | $190 |
| Prugen, Inc. Pharmaceuticals | 8 | $177 |
| Pfizer | 10 | $172 |
| Dermavant Sciences, Inc. | 12 | $169 |
| Journey Medical Corporation | 1 | $114 |
| Boehringer Ingelheim | 5 | $110 |
| Incyte Corporation | 5 | $99 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $73 |
| Mayne Pharma Commercial LLC | 8 | $55 |
| Galderma Laboratories, L.p. | 3 | $46 |
| Organogenesis Inc. | 2 | $35 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $28 |
| Biofrontera Inc. | 2 | $25 |
| Springworks Therapeutics, Inc. | 1 | $25 |
| Verrica Pharmaceuticals Inc. | 1 | $23 |
| Organon | 1 | $18 |
| Bristol Myers Squibb | 1 | $15 |
| Botanix SB Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,963 in reported general payments places this provider in the 85th percentile of 54 dermatopathology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 11 | $66,374 |
| Ivermectin | 12 | $4,441 |
| Mometasone Furoate | 133 | $2,602 |
| Clobetasol Propionate | 54 | $1,896 |
| Ketoconazole | 143 | $1,894 |
| Metronidazole | 20 | $1,766 |
| Fluocinolone Acetonide | 30 | $1,479 |
| Econazole Nitrate | 33 | $1,041 |
| Clindamycin Phosphate | 35 | $963 |
| Triamcinolone Acetonide | 89 | $960 |
| Tacrolimus | 11 | $830 |
| Fluocinonide | 23 | $779 |
| Betamethasone Dipropionate | 14 | $736 |
| Doxycycline Hyclate | 31 | $553 |
| ValacyclovirValacyclovir Hcl | 15 | $334 |
Paid to pharmacies, not to this prescriber.
Other dermatopathology in Austin
- Christopher ChuAustin$3K
- Brett KeelingAustin$116
- Angela MooreArlington$423K
- Melissa ChiangSpring$163K
- Alde GavinoLiberty Hill$110K
- Clay CockerellDallas$40K
- Michael TetzlaffHoustion$38K
- Matthew PetittPasadena$23K
- Miranda EwelukwaSugar Land$22K
- Andrew FischerHouston$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.